Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […] | ||
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […] | ||
Older | ||